1. Introduction
===============

The ADAMTS (a disintegrin and metalloproteinase domain with thrombospondin motifs) family includes 19 secreted proteinases in man. These enzymes have a complex domain structure consisting of at least a signal peptide, pro domain, metalloproteinase domain, disintegrin domain, thrombospondin type I motif and cysteine rich domain ([@bib25]). Phylogenetically, the enzyme family separates into eight clades which to some extent correlate with function where assigned ([@bib13]). ADAMTS-1, -4, -5, -8, -9 and -15 are all capable of degrading aggrecan at a specific set of loci with ADAMTS-5 being the major aggrecanase in cartilage destruction, at least in mice ([@bib4; @bib7; @bib12; @bib30]). At least three ADAMTS enzymes (ADAMTS-4, -7 and -12) can degrade cartilage oligomeric matrix protein, another component of cartilage ECM ([@bib10; @bib18; @bib19]). Three ADAMTS enzymes, ADAMTS-2, -3 and -14, are procollagen N-propeptidases (PCNPs), which have roles in collagen biosynthesis. ADAMTS-2 acts preferentially on type I collagen and ADAMTS-3 on type II collagen, whereas the preference of ADAMTS-14 is currently unknown ([@bib6]). Mutation of the *ADAMTS2* gene causes Ehlers--Danlos syndrome Type VIIC in man ([@bib5]). ADAMTS-13 cleaves von Willebrand factor with mutations in this enzyme leading to an inherited thrombotic thrombocytopenia ([@bib32]). A form of Weill--Marchesani syndrome is caused by mutation in the *ADAMTS10* gene ([@bib8]).

*ADAMTS-16* is a recently described member of the *ADAMTS* gene family ([@bib25]). The cDNA was cloned using a combination of bioinformatics and degenerate RT-PCR, which also identified ADAMTS-13, -14, -15, -17, -18 and -19 ([@bib2]). Amino acid sequence alignment showed a significant percentage of identity between ADAMTS-16 and ADAMTS-18 (overall identity, 57%), particularly in the catalytic domain where identity reaches 85% ([@bib25]). Indeed, the zinc-binding motif is identical between these two proteinases (HESGHNFGMIHD) ([@bib28]). ADAMTS-16 and -18 form a phylogenetic clade, with the nearest evolutionary neighbours being ADAMTS-6, -7, -10 and -12.

Whilst the substrates for ADAMTS-16 are currently unknown, a recombinant truncated form of ADAMTS-16 shows weak aggrecanase activity ([@bib33]) and full length recombinant ADAMTS-16 is capable of cleaving the proteinase inhibitor α~2~-macroglobulin ([@bib11]).

An initial expression analysis in a selection of human tissues shows high expression of *ADAMTS16* mRNA in fetal lung and kidney, and adult brain and ovary ([@bib2]). In this latter tissue, *ADAMTS16* is expressed predominantly in the parietal granulosa cells of pre-ovulatory follicles. Expression of the gene can be induced by follicle-stimulating hormone and forskolin in granulosa cells, suggesting that the cAMP pathway may be involved in its regulation in this system ([@bib11]). *ADAMTS16* has also recently been genetically linked to inherited hypertension ([@bib14]).

We undertook the expression profiling of all *ADAMTS* genes in cartilage and synovium. We compared expression in patients undergoing hip replacement for osteoarthritis (OA) to phenotypically normal tissues from patients undergoing hip replacement following fracture to the neck of femur. In cartilage, the expression of *ADAMTS16* increased in the OA samples with a significance of *p* \< 0.001, comparable to the increase in expression of *MMP13*, a collagenase whose activity is pathognomic with cartilage destruction in OA. This was backed up with a preliminary study in the knee using cartilage from OA patients compared to normal cartilage from post-mortem, where a similar increase in expression of these two genes was measured ([@bib15]). Similarly, in synovium, the expression of *ADAMTS16* was significantly increased in OA with the absolute level of *ADAMTS16* mRNA approximately 10-fold higher in synovium than in cartilage ([@bib9]).

In order to provide some insight into the regulation and function of ADAMTS-16 in the joint, the current study examines the expression of ADAMTS-16 by chondrocytes, the regulation of the gene and the consequence of stable over-expression of the gene in chondrosarcoma and immortalized chondrocyte cell lines.

2. Results
==========

2.1. Characterisation of ADAMTS16 and creation of stably expressing cell lines
------------------------------------------------------------------------------

Using PCR primer pairs to amplify overlapping sections of the *ADAMTS16* gene, the entire transcript was amplified from cDNA reverse transcribed from mRNA purified from an immortalized human chondrocyte cell line, C28/I2 ([@bib21]) (data not shown). No evidence for expression of splice variants was found (though it is possible that some truncated forms of the transcript might not have been detected if they were not amplified at all by selected primers). Based on these data, a full length cDNA was cloned and the final cDNA verified by sequencing in both directions. It should be noted that, despite using high fidelity polymerases and low numbers of amplifications cycles, frequent mutations were introduced by the PCR. The correct version of *ADAMTS16* could only be created by amplifying sections of the gene (up to approximately 1000 bp), verifying sequence, then assembling via restriction digestion and ligation into an error-free cDNA.

Initially, both immortalized chondrocytes (C28/I2) and chondrosarcoma (SW1353) cells were transfected with the full length *ADAMTS16* construct (with a C-terminal FLAG tag). However, the C28/I2 transfectants did not grow robustly after selection and experiments were pursued in the SW1353 line alone. Following cloning by limiting dilution, four different clonal populations expressing *ADAMTS16* (TS16) were compared to two clonal populations transfected with vector only control constructs (VO). Expression of *ADAMTS16* at the mRNA level was confirmed using qRT-PCR ([Fig. 1](#fig1){ref-type="fig"}a). The *ADAMTS16* expressing clones had an average of approximately 95-fold higher expression than the vector only controls. Western blot using both an anti-ADAMTS-16 antibody and an anti-FLAG antibody showed expression of a high molecular weight (\~ 130 kDa) protein predominantly in the extracellular matrix fraction of the ADAMTS16 transfectants ([Fig. 1](#fig1){ref-type="fig"}b). Two bands of similar size were also detected in the conditioned medium and cell lysate fractions ([Fig. 1](#fig1){ref-type="fig"}c).

2.2. Influence of ADAMTS-16 on expression levels of other metzincin genes
-------------------------------------------------------------------------

Expression levels of all 19 members of the ADAMTS family, all four members of the TIMP gene family and MMP2, MMP9, MMP13 and MMP28 were determined in cells stably over-expressing ADAMTS16 compared to vector only controls using qRT-PCR. The representatives of the MMP family were chosen because of their expression pattern in tissues of the OA joint ([@bib9; @bib15]). MMP13 expression levels were significantly reduced in ADAMTS16-expressing clones compared to vector only controls (*p* \< 0.005; [Fig. 1](#fig1){ref-type="fig"}d) with a mean of approximately 9-fold lower expression. Interestingly, the level of MMP13 expression was inversely correlated with that of ADAMTS16 (compare [Fig. 1](#fig1){ref-type="fig"}a and d). Expression levels of the other genes analysed did not change significantly between over-expressing cells and vector only controls (data not shown).

2.3. Effects of ADAMTS16 expression on cell phenotype
-----------------------------------------------------

Expression of ADAMTS-16 by stably expressing clones was confirmed by immunocytochemistry using anti-FLAG antibodies ([Fig. 2](#fig2){ref-type="fig"}a). Protein was detected only in permeabilized cells, with cytoplasmic and some perinuclear staining. No staining was observed in vector only controls or non-immune IgG controls. Cells stably over-expressing *ADAMTS16* were larger and more elongated than vector only controls ([Fig. 2](#fig2){ref-type="fig"}b) which were not significantly different from non-transfected SW1353 cells. These differences were observed at all stages of confluence. The ability of cells to adhere to extracellular matrix proteins (collagen I, collagen II, fibronectin and vitronectin) was measured and no significant difference was observed between *ADAMTS16* over-expressing cells and vector only controls (data not shown). Cell proliferation was measured by uptake of tritiated thymidine, a direct measure of DNA replication. This showed that proliferation of over-expressing cells was significantly reduced in all four clones in medium containing 0.5% FCS compared to vector only controls (*p* \< 0.001 comparing *ADAMTS16*-expressing cells vs. vector only; [Fig. 3](#fig3){ref-type="fig"}). Proliferation was similarly reduced in cells growing in medium containing 10% FCS though with lower significance (*p* = 0.01). Migration of cells measured using time-lapse microscopy also showed that *ADAMTS16* over-expressing cells had significantly reduced migration on plastic compared to vector only controls (*p* \< 0.005, comparing mean of *ADAMTS16*-expressing cells vs. vector only; [Fig. 4](#fig4){ref-type="fig"}).

2.4. Regulation of ADAMTS16 by growth factors and cytokines
-----------------------------------------------------------

Of a number of growth factors and cytokines tested (IL-1, TNF-α, TGF-β1, IGF-1, IFN-γ, IL-6, IL-6, IL-4, IL-10, IL-11, IL-17, OSM, EGF, BMP-2, BMP-7), only TGFβ was found to regulate levels of endogenous *ADAMTS16* expression in chondrocyte cell lines. TGFβ induced mRNA expression at the steady state mRNA level in both SW1353 and C28/I2 cells in a dose-dependent manner ([Fig. 5](#fig5){ref-type="fig"}).

2.5. Identification of the transcription start site and minimal promoter
------------------------------------------------------------------------

[Fig. 6](#fig6){ref-type="fig"} shows the alignment of 1000 base pairs (bp) of sequence upstream of the translation start site of *ADAMTS16* for human, chimp, macaque and mouse. This alignment revealed a number of conserved regions (indicated '⁎' in [Fig. 6](#fig6){ref-type="fig"}) that potentially indicate regulatory sequences, with no strong TATA sequence. The predicted translation start site (ATG) is conserved amongst the primates, but not in mouse which appears to use a downstream ATG. This latter sequence is conserved in primates, but not in frame with the upstream primate ATG.

The longest PCR products obtained using 5′ RLM-RACE indicate that the transcription start site lies 138 bp upstream of the ATG in the human gene. [Fig. 7](#fig7){ref-type="fig"}a shows the PCR products obtained by performing 5′ RLM-RACE on RNA from three different sources (C28/I2 cells stimulated with TGFβ, ovary and HeLa cells). [Fig. 7](#fig7){ref-type="fig"}b shows the position of the primer SP2 used for RLM-RACE and the predicted transcription start point. This site is in agreement with an mRNA transcript of *ADAMTS16* deposited in Genbank ([NM_139056](ncbi-n:NM_139056)). Primer extension using primer SP2 also detected a band of approximately the same size as the RACE products (data not shown).

Eight fragments of the 5′ region of *ADAMTS16* ranging from +110/+138 to − 1802/+138 (marked on [Fig. 6](#fig6){ref-type="fig"}) were cloned into a luciferase reporter vector. Analysis of reporter activity ([Fig. 8](#fig8){ref-type="fig"}) indicated that the minimal promoter lies between − 13 and + 25, encompassing the transcription start point identified above. Activity increased greatly in deletions from − 1802 to − 412 indicating the presence of a repressive element within this region. Successive deletions between − 412 and − 13 resulted in incremental decreases in activity, suggesting the presence of a number of transcription factor binding sites in these regions.

2.6. Identification of transcription factors activating the ADAMTS16 promoter
-----------------------------------------------------------------------------

The proximal promoter is GC rich and a search for transcription factor consensus sequences (MatInspector, Genomatix) revealed a number of both Sp1 and Egr1 binding sites ([Fig. 9](#fig9){ref-type="fig"}a). These factors have also been implicated in TGFβ signalling to extracellular matrix genes ([@bib3; @bib34]). Co-transfection of the *ADAMTS16* promoter constructs with expression vectors for each of these factors showed responsiveness to both transcription factors ([Fig. 9](#fig9){ref-type="fig"}b and c). Induction of the promoter by Egr1 is reduced by deletion from − 412 to − 157 and lost by further deletion to − 42 (with Egr1 repressing smaller constructs). All promoter constructs were induced by Sp1 and indeed there are further Sp1 sites downstream of the transcription start point.

3. Discussion
=============

ADAMTS-16 is a multi-domain protein encoded by 23 exons. Initially in this study, we verified that the full length transcript was expressed in chondrocyte cell lines and then cloned this cDNA into an expression construct with a C-terminal FLAG tag. Chondrosarcoma cells stably over-expressing ADAMTS-16 were selected and cloned. Over-expression of *ADAMTS16* was verified at the mRNA level by qRT-PCR and at the protein level by immunocytochemistry and western blot using the anti-FLAG antibody and/or an anti-ADAMTS-16 antibody (raised against a C-terminal peptide). Western blot showed an approximately 130 kDa band predominantly associated with the extracellular matrix fraction, with an additional higher molecular weight band faintly detected. The full length ADAMTS-16 polypeptide has a predicted molecular weight of 136 kDa, in good agreement with the experimental finding. A doublet around this molecular weight was also weakly detected in the cell lysate and conditioned medium of the *ADAMTS16* transfects. The lower molecular weight band corresponds to the major band in the ECM, suggesting that this is a processed form. Two 'in-house' anti-peptide antibodies raised against sequences in the propeptide and catalytic domain respectively recognise a band of approximately 65 kDa in conditioned medium (data not shown), though the specificity of these antibodies remains to be determined.

Whilst stably transfected SW1353 cells could be maintained and expanded, this wasn\'t the case for the C28/I2 transformed chondrocytes. In the SW1353 cells, over-expression of ADAMTS-16 lead to a reduction in cell proliferation and this change in phenotype may, in part, explain why the C28/I2 cells were not successfully expanded. SW1353 cells over-expressing ADAMTS-16 also showed a change in cell shape and a decrease in cell migration on plastic, though no difference in cell adhesion to a number of extracellular matrix proteins. This does not appear to be the consequence solely of stable transfection since similar cell lines over-expressing MMP-28 display a different phenotype ([@bib27]). Interestingly, ADAMTS-1 modifies both cell proliferation and migration dependent on cell type, domain content and concentration of the enzyme used ([@bib17; @bib20]).

Members of the metzincin family are known to process a number of growth factors, cytokines and signalling molecules in addition to matrix substrates ([@bib29]). Since the over-expression of ADAMTS-16 has no effect on expression levels of most of the *ADAMTS*, *TIMP* and *MMP* genes tested, it is unlikely that ADAMTS-16 processes factors that regulate these genes. However, our initial interests in ADAMTS-16 centred around the fact that in end stage osteoarthritis, the expression of the *ADAMTS16* gene is increased in cartilage and synovium in a way similar to that of MMP-13, a collagenolytic enzyme known to be involved in the destruction of tissues in the joint \[17, 18\]. Interestingly, the SW1353 cells over-expressing ADAMTS-16 display reduced expression of *MMP13* mRNA, though the mechanism or functional significance of this observation is unknown. There is no clear link in the literature between decreased *MMP13* expression and decreased proliferation or migration (as observed for *ADAMTS16* over-expressing cells). Indeed one agent, pleiotrophin, has recently been reported to induce proliferation and migration of chondrocytes whilst repressing *MMP13* expression ([@bib26]). In OA cartilage, other factors must override the repression of *MMP13* expression by increased ADAMTS-16 since both enzymes show increased expression compared to that in normal cartilage. Given the importance of MMP-13 as a collagenase in OA, the mechanistic link between ADAMTS-16 and *MMP13* expression is worthy of further investigation.

Since *ADAMTS16* expression was increased in OA tissues, we tested a number of growth factors and cytokines implicated in this disease for their ability to regulate expression of the *ADAMTS16* gene *in vitro*. In both C28/I2 and SW1353 cells, TGFβ induced expression of *ADAMTS16* in a dose-dependent fashion. TGFβ has been reported to induce *MMP13* expression in chondrocytes ([@bib22]) and there is evidence to demonstrate a role for this growth factor in the development or progression of osteoarthritis ([@bib1]).

Sequence alignment shows a high level of conservation between primates and mouse in the 5′ upstream region of the *ADAMTS16* gene. 5′ RACE gives a transcription start point 138 bp upstream of the translation start point and this is in agreement with both primer extension data and the end of exon 1 given in Ensembl ([www.ensembl.org](http://www.ensembl.org)). Interestingly, the sequence across the transcription start point (− 2/+5, 5′TCAGTAA3′) is a putative AP-1 binding site. This is contrary to the computer prediction of the transcription start point at 560 bp upstream of the translation start point (− 422 from the transcription start point) and the associated promoter reported in Gao et al. ([@bib11]), however it is possible that the gene has greater than one transcription start point.

A deletion analysis from − 1802 (relative to the transcription start point) showed that constructs expressed promoter activity only when they encompassed the transcription start point. Promoter activity increased with the increasing length to − 412, a region which is GC rich and contains many putative binding sites for transcription factors such as Sp1 and Egr1. Interestingly, these factors have previously been implicated in TGFβ signalling, with both factors involved in the induction of type I collagen by TGFβ ([@bib3; @bib34]). Forced over-expression of these factors demonstrates that both factors are capable of inducing the *ADAMTS16* promoter. Egr1 induction appears to be mediated mainly by the − 412/− 157 region, with Sp1 induction also mediated through further downstream sequences.

In summary, over-expression of ADAMTS-16 leads to decreased cell proliferation and migration either directly, or indirectly via changes in gene expression e.g. *MMP13*. Expression of *ADAMTS16* is induced by TGFβ and we have experimentally identified the transcription start point of the gene, its promoter, and two relevant activating transcription factors. Overall, these data provide new information on the function and regulation of ADAMTS-16 in chondrocyte cell lines.

4. Experimental procedures
==========================

4.1. PCR and cloning of full length transcript
----------------------------------------------

RNA was extracted from C28/I2 immortalised human chondrocyte cells ([@bib21]) using TRIzol^®^ reagent (Invitrogen) and adding 0.5× volume of chloroform. The aqueous phase was recovered after centrifugation at 12,000 rpm for 15 min at 4 °C and added to an equal volume of isopropanol. RNA was pelleted by centrifugation at 12,000 rpm for 30 min at 4 °C and washed with 70% ethanol. RNA was eluted into distilled water and quantified using a NanoDrop^®^ spectrophotometer (Nanodrop Technologies). cDNA was synthesized from 1 µg of RNA using Superscript^TM^ II reverse transcriptase (Invitrogen) and random hexamers, according to the manufacturer\'s recommendations. PCRs were performed using 50 ng of cDNA template, 0.5 µM each primer, 200 µM dNTPs and 0.5 U of AccuTaq^TM^ LA polymerase (Sigma-Aldrich) in the manufacturer\'s buffer, in a PTC-100 thermal cycler (MJ Research). PCR products were visualised on 1% agarose gels stained with ethidium bromide. For cloning, PCR primers at each end of the gene were tagged with four random nucleotides (italics) and an EcoRI (5′) and NotI (3′) restriction enzyme recognition site (underlined). The 5′ forward primer also contained a consensus Kozak sequence (bold; ([@bib16])). Primer sequences were as follows: 5′-*ACGTGAATTC***GCCGCCACC**ATGAAGCCCCGCGCG-3′ and 5′-*ACGTGCGGCCGC*CCAAGTTGGACTTAGAGCAAG-3′ for forward and reverse primers respectively. PCR products were digested with EcoRI and NotI and ligated into a modified version of the pcDNA4^TM^ expression vector (Invitrogen) expressing an in frame C-terminal FLAG-tag. Sequencing of the cloned gene was performed in both directions using BigDye^TM^ v.3.1 terminator sequencing chemistry (Applied Biosytems) on an ABI Prism^®^ 3730 capillary sequencer (Applied Biosystems).

4.2. Creation of stably expressing cell lines
---------------------------------------------

SW1353 human chondrosarcoma cells (ATCC) or immortalized C28/I2 chondrocytes were cultured in DMEM plus GlutaMAX^TM^ (Invitrogen) with 10% fetal calf serum (FCS; Invitrogen). 100,000 cells per well were plated into 6-well plates and incubated overnight. The *ADAMTS16*/pcDNA4-FLAG construct was linearised by digesting with BglII and 1 µg was transfected into cells using FuGENE^®^6 transfection reagent (Roche) according to the manufacturer\'s recommendations. After 48 h, cells were switched to culture medium containing 200 µg/ml zeocin (Melford Laboratories). After 7 days, surviving cells were plated into 96-well plates containing three, one and 0.3 cells/well. Wells containing cells were expanded and plated again into 96-well plates containing three, one and 0.3 cells/well to select for clonal colonies originating from single cells. Cells were maintained in zeocin-containing media.

4.3. Quantitative real-time PCR
-------------------------------

Cells were plated into 6-well plates containing 200,000 cells/well in triplicate. After 24 h, cells were changed to serum-free media and incubated for a further 24 h. RNA extraction and cDNA synthesis were performed as before. Primers and fluorescent probes for *ADAMTS16* and all of the *ADAMTS*s, *MMP*s and *TIMP*s were designed using Primer Express 1.0 software (Applied Biosystems) and are described elsewhere ([@bib23; @bib24]). The *18S* rRNA gene was used as an endogenous control to normalise for differences in the amount of RNA between samples. Primers and probe for 18S were obtained from Applied Biosystems. Quantitative PCRs were performed and analysed as described previously ([@bib9]).

4.4. Immunocytochemistry
------------------------

Stably transfected SW1353 cells were plated into chamber slides at a density of 10,000 cells/well. After incubating for 24 h, cells were switched to serum-free media for a further 24 h. Cells were fixed using 4% paraformaldehyde, blocked with 3% BSA and incubated with a 1:5000 dilution of mouse ANTI-FLAG^®^ M2 IgG monoclonal antibody (Sigma) and a 1:1000 dilution of FITC-labelled rabbit anti-mouse IgG secondary antibody (Dako). Nuclei were stained with 2.5 µg/ml DAPI. Cells were also incubated with mouse IgG and secondary antibody as before as a control. Cells were visualised using an AxioPlan 2ie confocal microscope with Axiovision software (Carl Zeiss).

4.5. Western blot analysis
--------------------------

Stably transfected SW1353 cells were plated at 100,000/well of a 6-well plate. After 24 h cells were switched to serum-free medium for a further 48 h. The conditioned media was collected and proteins precipitated with 0.5 vol. of 10% (v/v) trichloroacetic acid (TCA) for 1 h on ice. Samples were centrifuged for 15 min at 13,000 rpm, and pellets washed with cold acetone and pelleted for a further 15 min at 13,000 rpm. Protein pellets were air-dried and resuspended in 1 × SDS final sample buffer (0.058 M Tris-HCl, pH 6.8; 5% v/v glycerol; 1.7% w/v SDS and 0.002% w/v bromophenol blue) containing 50 mM DTT and 6 M urea (FSB/DTT/urea). Cells were detached with 0.5 mM EDTA in PBS. Cell pellets were collected by centrifugation at full speed for 5 min, resuspended in FSB/DTT/urea and sonicated prior to analysis. ECM proteins were harvested by scraping each well with FSB/DTT/urea for approximately 30 s/well. All samples were boiled for 5 min and subjected to western blotting. Proteins were separated by SDS-PAGE, followed by transfer to PVDF membrane. ADAMTS-16 was probed using a 1:5000 dilution of mouse ANTI-FLAG^®^ M2 IgG monoclonal antibody (Sigma-Aldrich) followed by a 1:1000 dilution of HRP-labelled rabbit anti-mouse IgG secondary antibody (Dako, Denmark). An antibody raised against a 75 amino acid peptide from the C-terminal thrombospondin repeat domain of human ADAMTS-16 (Santa Cruz SC-50490) were used to verify expression. LumiGLO reagent and peroxide (Cell Signalling Technology, Beverley, MA) were used for detection on Kodak Biomax MS film (Sigma-Aldrich) by chemiluminescence.

4.6. Adhesion, proliferation and migration assays
-------------------------------------------------

96-well culture plates were coated with 50 µg/ml of vitronectin or fibronectin or 100 µg/ml of collagens I or II overnight at 4 °C. Plates were blocked with 1% BSA for 1 h at 37 °C before adding 30,000 cells/well. After 15 min, plates were washed six times with PBS. Cell adhesion was measured using a Cell Titer 96^®^ AQueous One Solution Cell Proliferation Assay kit (Promega), according to the manufacturer\'s recommendations. For proliferation assays, cells were plated in medium containing 10% FCS at 25,000 cells/well in 24 well plates in replicates of six and allowed to adhere overnight. Each well was labelled with 0.5 µCi per well \[6-^3^H\]-thymidine for 6 h in either medium containing 10% or 0.5% FCS, washed twice with HBSS and fresh medium added containing 3 µM cold thymidine. After overnight incubation, medium was aspirated and 300 µl/well 0.25 M ammonia added. Plates were rocked for 2 h at room temperature and lysate from each well transferred into scintillant for counting tritium. For migration assays, cells were plated at 10,000 cells/well in 24-well plates. After 8 h cells were subjected to time-lapse microscopy on an AxioVert 200 M microscope that was enclosed in an Incubator XL (Carl Zeiss) for temperature and CO~2~ control. Cells were photographed at 15 min intervals for 13 h. Total distance moved (in µm) for 10 cells/well was measured using Axiovision Software (Carl Zeiss).

4.7. Induction with cytokines and growth factors
------------------------------------------------

SW1353 cells were plated into six-well plates at 200,000 cells per well. After 24 h cells were transferred into serum-free media. Cells were incubated with each factor in triplicate for 6 h for Taqman analysis. RNA extraction, cDNA synthesis and TaqMan^®^ real-time PCR were performed as described above for analysis of *ADAMTS16*.

4.8. Promoter alignment
-----------------------

The 5′ upstream region of human *ADAMTS16* was obtained and aligned with chimp, macaque and mouse using the Ensembl database [www.ensembl.org](http://www.ensembl.org).

4.9. 5′ RACE
------------

5′ RLM-RACE was performed using a GeneRacer^TM^ kit (Invitrogen) according to the manufacturer\'s recommendations. The primer 5′TGGAAAAGGGCGAATATGAC3′ (SP2) was used to generate amplified products which were cloned using a TOPO-TA cloning kit (Invitrogen) according to the manufacturer\'s recommendations. DNA sequencing was performed using the M13 universal primers supplied with the kit.

4.10. Cloning of a deletion set and luciferase reporter assays
--------------------------------------------------------------

Genomic DNA was extracted from cultured SW1353 cells using a QIAamp DNA Mini Kit (Qiagen) according to the manufacturer\'s recommendations. PCR products were obtained using 50 ng of genomic DNA template, 0.5 µM of each primer, (synthesised with a 5′ MluI recognition site) 200 µM dNTPs and 0.5 U of AccuTaq^TM^ LA polymerase (Sigma-Aldrich) in the manufacturer\'s buffer, in a PTC-100 thermal cycler (MJ Research). For fragments of 29 bp and 54 bp, synthetic oligonucleotides were manufactured. Fragments were run on 1% agarose gels stained with ethidium bromide, digested with MluI and cloned into the MluI site of the pGL3-basic luciferase reporter vector (Promega). Insert orientation was verified by sequencing using pGL3 sequencing primers. SW1353 cells were plated into 24-well plates at 20,000 cells/well. Each pGL3 construct was transfected in triplicate using 200 ng DNA and FuGENE^®^6 transfection reagent (Roche), according to the manufacturer\'s recommendations. After 24 h cells were lysed and assayed using a Luciferase Reporter Gene Assay kit (Roche) following the manufacturer\'s recommendations. Transfections were performed with at least two different isolates of each plasmid. The Sp1 cDNA was a kind gift from Professor G. Suske (Marburg, Germany) and was subcloned into the pcDNA4 vector (above). The Egr1 expression construct was as previously described ([@bib31]).
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![Stable over-expression of *ADAMTS16* in SW1353 cells. SW1353 cells were stably transfected with either vector only (VO) or ADAMTS16 (TS16) expression constructs. Cells were harvested and total RNA isolated and subjected to qRT-PCR for expression of (a) *ADAMTS16* or (d) *MMP13*. Data are normalized to 18 S and expressed as mean ± s.e.m. Mean threshold cycle (Ct) is given above each bar. Extracellular matrix (b) or cell lysate and conditioned medium (c) were harvested (VO vs. TS16) and subjected to western blot analysis using anti-ADAMTS-16 and/or anti-FLAG primary antibodies.](gr1){#fig1}

![Effect of ADAMTS-16 on cell phenotype. SW1353 cells were stably transfected with either vector only (VO) or ADAMTS16 (TS16) expression constructs. (a) Cells were fixed in 4% paraformaldehyde and stained with a 1:5000 dilution of mouse anti-FLAG antibody followed by FITC-linked second antibody; nuclei were counterstained with DAPI. (b) Cells were visualised under phase contrast 72 h after plating on plastic (×10 objective).](gr2){#fig2}

![Proliferation of SW1353 cells stably expressing *ADAMTS16*. SW1353 cells were stably transfected with either vector only (VO) or ADAMTS16 (TS16) expression constructs. Cells were allowed to adhere overnight in DMEM/10% FCS then treated with 3H-thymidine in DMEM/0.5% FCS for 6 h followed by an overnight cold chase. Cell lysates were harvested and counted for tritium. Data are expressed as mean ± s.e.m., ⁎*p* \< 0.05; ⁎⁎*p* \< 0.01, ⁎⁎⁎*p*\<0.001 comparing TS16 with either VO-1 or VO-2.](gr3){#fig3}

![Cell migration of SW1353 cells stably expressing *ADAMTS16*. SW1353 cells were stably transfected with either vector only (VO) or ADAMTS16 (TS16) expression constructs. Eight hours after plating in DMEM/10% FCS, cells were subjected to time-lapse microscopy at 15 min intervals for 13 h. Distance moved per cell was averaged for 10 cells. Data are expressed as mean ± s.e.m., ⁎*p* \< 0.05; ⁎⁎*p* \< 0.01, ⁎⁎⁎*p*\<0.001 comparing TS16 with VO-1 or VO-2.](gr4){#fig4}

![Induction of *ADAMTS16* expression by TGFβ. Confluent C28/I2 cells were serum starved for 24 h prior to addition of TGFβ for 6 h followed by harvest of RNA and qRT-PCR for *ADAMTS16*. Data are expressed as mean ± s.e.m., ⁎*p* \< 0.05; ⁎⁎*p* \< 0.01.](gr5){#fig5}

###### 

Sequence alignment for *ADAMTS16* putative promoter region. Sequence alignment of 1000 bp upstream of *ADAMTS16* ATG from human, macaque, chimp and mouse ([www.ensembl.org](http://www.ensembl.org)). ⁎Indicates conserved regions. Translation start codon is shaded in grey with transcription start point (TSP) also marked. The 5′ positions of the deletion set of promoter--reporter constructs are also shown (arrows).
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![Identification of transcription start point in *ADAMTS16* gene. 5′ RNA ligase-mediated (RLM) RACE was undertaken using C28/I2, human ovary or HeLa cell cDNA templates. (a) An agarose gel of the PCR products is shown; (b) following sequencing of RACE products, the transcription start point is marked as +1, translation start codon is shaded grey and position of RACE primer is shown (arrow).](gr7){#fig7}

![Promoter activity in the *ADAMTS16* gene. SW1353 cells were transiently transfected with promoter--reporter fragments in pGL3-basic as shown. Luciferase activity (measured as relative light units) of untransfected cells (control) and transient transfections of empty vector (pGL3) and eight deletion constructs ranging from − 1802/+138 to +110/+138 are plotted as mean ± s.e.m.](gr8){#fig8}

![Activation of the *ADAMTS16* promoter by Egr1 and Sp1. SW1353 cells were transiently transfected with promoter--reporter fragments in pGL3-basic as shown and co-transfected with expression constructs for Egr1, Sp1 or empty vector. Luciferase activity is plotted as fold compared to empty vector, mean ± s.e.m.; ⁎*p* \< 0.05; ⁎⁎*p* \< 0.01; ⁎⁎⁎*p* \< 0.001. (a) schematic representation of Egr1 and Sp1 consensus sequences in the *ADAMTS16* promoter; (b) induction of promoter by Egr1; (c) induction of promoter by Sp1.](gr9){#fig9}
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